Abstract：【Objective】 To compare the efficacy and safety of levodopa-benserazide and compound carbidopa in the treatment of patients with early Parkinson's disease (PD).【Methods】 A total of 180 PD patients were randomly divided into the observation group and the control group, with 90 cases in each group. The control group was treated with levodopa-benserazide, while the observation group was treated with compound carbidopa. The efficacy, incidence of adverse reactions, and changes in scores of Part Ⅱ (daily activities, UPDRSⅡ) and Part Ⅲ (motor function, UPDRSⅢ) of the Unified Parkinson's Disease Rating Scale (UPDRS) and Parkinson's Disease Questionnaire-39 (PDQ-39) before and after treatment were compared between the two groups.【Results】After 12 weeks of treatment, there was no significant difference in the total effective rate between the two groups (P>0.05). From pre-treatment to 12 weeks after treatment, the scores of UPDRSⅡ, UPDRSⅢ, and PDQ-39 in both groups gradually decreased with the extension of time, and the differences at each time point were statistically significant (P<0.05). There were no significant differences in UPDRSⅡ, UPDRSⅢ, and PDQ-39 scores between the two groups before and at each time point after treatment (P>0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05).【Conclusion】The efficacy of levodopa-benserazide tablets and compound carbidopa in the treatment of early PD is comparable, however, compound carbidopa has higher safety.
李晓霞, 夏欢, 严润, 黄惠英, 胡佳, 郭永华, 易蕾. 多巴丝肼与复方卡比多巴治疗早期帕金森病患者的疗效比较*[J]. 医学临床研究, 2025, 42(8): 1304-1306.
LI Xiaoxia, XIA Huan, YAN Run, et al. Comparison of Efficacy between Levodopa-Benserazide and Compound Carbidopa in the Treatment of Early Parkinson's Disease. JOURNAL OF CLINICAL RESEARCH, 2025, 42(8): 1304-1306.
2025, Vol. 42 
